SSTR2 and neuroendocrine neoplasm: [225Ac]Ac-DOTATATE (RYZ101), an SSTR2 agonist, is currently being evaluated in a phase Ib/III clinical trial in patients with SSTR2-positive gastro-enteropancreatic neuroendocrine tumors that have progressed after treatment with [177Lu]Lu-labeled agonists and compared to SoC (ACTION-1, NCT05477576).